ABB
ABB is today launching an innovative all-in-one Electric Vehicle (EV) charger , which provides the fastest charging experience on the market.
ABB’s new Terra 360 is a modular charger which can simultaneously charge up to four vehicles with dynamic power distribution. This means that drivers will not have to wait if somebody else is already charging ahead of them. They simply pull up to another plug. The new charger has a maximum output of 360 kW and is capable of fully charging any electric car in 15 minutes or less, meeting the needs of a variety of EV users, whether they need a fast charge or to top their battery up while grocery shopping.
“With governments around the world writing public policy that favors electric vehicles and charging networks to combat climate change, the demand for EV charging infrastructure, especially charging stations that are fast, convenient and easy to operate is higher than ever,” said Frank Muehlon, President of ABB’s E-mobility Division. “The Terra 360, with charging options that fit a variety of needs, is the key to fulfilling that demand and accelerating e-mobility adoption globally.”
“It’s an exciting day for ABB, who as the global leader in electric vehicle fast charging, is playing a key role in enabling a low carbon society,” said Theodor Swedjemark, Chief Communications and Sustainability Officer at ABB. “With road transport accounting for nearly a fifth of global CO2 emissions, e-mobility is critical to achieving the Paris climate goal. We will also lead by example by switching our entire fleet of more than 10,000 vehicles to non-emitting vehicles.”
Available in Europe from the end of 2021, and in the USA, Latin America and Asia Pacific regions in 2022, Terra 360 is designed with the daily needs and expectations of EV drivers in mind. Leveraging the rich field experience gained by ABB E-mobility’s large installed base, the Terra 360 delivers speed and convenience along with comfort, ease-of-use and a sense of familiarity.
Its innovative lighting system guides the user through the charging process and shows the State of Charge (SoC) of the EV battery and the residual time before the end of an optimal charge session. The world’s fastest EV charger is also wheelchair accessible and features an ergonomic cable management system that helps drivers plug in quickly with minimal effort.
As well as serving the needs of private EV drivers at fueling stations, convenience stores and retail locations, Terra 360 chargers can also be installed on an organization’s commercial premises to charge electric fleet cars, vans and trucks. This gives owners the flexibility to charge up to four vehicles overnight or to give a quick refill to their EVs in the day. Because Terra 360 chargers have a small footprint, they can be installed in small depots or parking lots where space is at a premium.
Terra 360 chargers are fully customizable. To personalize the appearance, customers can ‘brand’ the chargers by using different foiling or changing the color of the LED light strips. There is also the option to include an integrated 27” advertisement screen to play video and pictures.
ABB is a world leader in electric vehicle infrastructure, offering the full range of charging and electrification solutions for electric cars, electric and hybrid buses, vans, trucks, ships and railways. ABB entered the e-mobility market back in 2010, and today has sold more than 460,000 electric vehicle chargers across more than 88 markets; over 21,000 DC fast chargers and 440,000 AC chargers, including those sold through Chargedot.
ABB high-power chargers are already being deployed around the world through the company’s partnerships with international charging operators such as IONITY and Electrify America.
To explore ABB’s electric vehicle charging technology, visit www.abb.com/ev-charging .
ABB (ABBN: SIX Swiss Ex) is a leading global technology company that energizes the transformation of society and industry to achieve a more productive, sustainable future. By connecting software to its electrification, robotics, automation and motion portfolio, ABB pushes the boundaries of technology to drive performance to new levels. With a history of excellence stretching back more than 130 years, ABB’s success is driven by about 105,000 talented employees in over 100 countries. www.abb.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210929006025/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom